Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M701006200 on June 14, 2007

J. Biol. Chem., Vol. 282, Issue 32, 23509-23516, August 10, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/32/23509    most recent
M701006200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, V. E.
Right arrow Articles by Shrier, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, V. E.
Right arrow Articles by Shrier, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Co-chaperone FKBP38 Promotes HERG Trafficking*

Valerie E. Walker, Roxana Atanasiu, Hung Lam, and Alvin Shrier1

From the Department of Physiology, McGill University, Montreal, Quebec H3G 1Y6, Canada

Received for publication, February 2, 2007 , and in revised form, June 1, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Long QT Syndrome is a cardiac disorder associated with ventricular arrhythmias that can lead to syncope and sudden death. One prominent form of the Long QT syndrome has been linked to mutations in the HERG gene (KCNH2) that encodes the voltage-dependent delayed rectifier potassium channel (IKr). In order to search for HERG-interacting proteins important for HERG maturation and trafficking, we conducted a proteomics screen using myc-tagged HERG transfected into cardiac (HL-1) and non-cardiac (human embryonic kidney 293) cell lines. A partial list of putative HERG-interacting proteins includes several known components of the cytosolic chaperone system, including Hsc70 (70-kDa heat shock cognate protein), Hsp90 (90-kDa heat shock protein), Hdj-2, Hop (Hsp-organizing protein), and Bag-2 (BCL-associated athanogene 2). In addition, two membrane-integrated proteins were identified, calnexin and FKBP38 (38-kDa FK506-binding protein, FKBP8). We show that FKBP38 immunoprecipitates and co-localizes with HERG in our cellular system. Importantly, small interfering RNA knock down of FKBP38 causes a reduction of HERG trafficking, and overexpression of FKBP38 is able to partially rescue the LQT2 trafficking mutant F805C. We propose that FKBP38 is a co-chaperone of HERG and contributes via the Hsc70/Hsp90 chaperone system to the trafficking of wild type and mutant HERG potassium channels.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Long QT Syndrome is a cardiac disorder characterized by a prolongation of the QT interval on the surface electrocardiogram that has been associated with ventricular arrhythmias whose clinical features range from minor dizziness to seizure, syncope, and sudden death. One prominent form of the Long QT syndrome (LQT2)2 is localized to chromosome 7 (1) and has been linked to genetic mutations in the KCNH2 gene that encodes the HERG subunit. The HERG channel is a tetramer of HERG subunits that comprises the {alpha}-subunit of the voltage-dependent delayed rectifier potassium current (IKr) (2). To date, more than 200 naturally occurring LQT2 mutants have been identified that result in either abnormal HERG channel function or a decrease in cell surface localization. Approximately 13% of these HERG mutations are characterized as trafficking-deficient mutants and represent the most dominant mechanism for the loss of HERG function in LQT2 (3). HERG trafficking mutants represent a potential target for pharmacological intervention as roughly 70% can be rescued, suggesting that the folding defects might be subtle (3). Under physiological conditions wild type (WT) HERG exhibits two bands on Western blot analysis, with the generation of both bands involving asparagine (Asn)-linked glycosylation (4). The core-glycosylated, immature form is represented by a 135-kDa band and is present in the endoplasmic reticulum (ER), whereas the fully glycosylated mature protein is observable as a 155-kDa band and represents HERG either in the Golgi apparatus or at the cell surface (5, 6). Comparison of the intensity of these two bands provides a useful assay of HERG trafficking.

The prevailing view is that mutants with trafficking deficiencies are recognized and retained as misfolded proteins by the quality control machinery of the ER (7). Recently, it has been reported that HERG forms complexes with the molecular chaperones Hsc70 (70-kDa heat shock cognate protein), Hsp90 (90-kDa heat shock protein) (8), and calnexin (9), which are known to be important for polypeptide folding, sorting, transport, and degradation (10, 11). Ficker et al. (8) demonstrated that two LQT2-trafficking mutants, R752W and G601S, also interacted with Hsc70 and Hsp90 when retained in the ER and these interactions were prolonged relative to WT HERG. The recovery of channel trafficking and function by temperature reduction or pharmacological stabilization was tightly coupled to the dissociation of channel-chaperone complexes (8). This finding suggests that the Hsc70 and Hsp90 chaperone system is important for the folding of HERG and that regulation of exit from the ER is mechanistically linked to the dissociation of HERG from this complex. The Hsc70/Hsp90 network has been characterized more extensively for the cystic fibrosis transmembrane conductance regulator (CFTR) (12, 13) and the glucocorticoid receptor (14). Thus far, interactions have been identified between CFTR and Hsc70 (15), calnexin (16), Hsp90 (17), Hdj-2 (18, 19), C-terminal of Hsp70-interacting protein (CHIP) (20-22), and Bcl-2-associated athanogene 2 (BAG-2) (22). However, little is known about the protein complexes that form between HERG and molecular chaperones to facilitate HERG folding, maturation, and retention.

To identify additional possible HERG-interacting chaperones we conducted a proteomic analysis. This revealed several known cytosolic chaperones, including Hsc70, Hsp90, Hdj-2, Hsp-organizing protein (Hop), and Bag-2 as well as two transmembrane proteins that included calnexin and FKBP38 (38-kDa FK506-binding protein, FKBP8). FKBP38 is of particular interest in that it is almost entirely exposed to the cytosol and is related to the known tetratricopeptide repeat (TPR) domain co-chaperone FKBP52 (23). It contains an N-terminal region of unknown function, an FK506 binding peptidylprolyl cis/trans isomerase domain, a TPR domain predicted to interact with Hsc70 and/or Hsp90, a calmodulin binding motif, and a C-terminal transmembrane anchor (24). The TPR domain of FKBP38 is closely related to the TPR domain present in co-chaperones of Hsc70 and Hsp90. Some co-chaperone TPR domains, such as those in Hop, specifically distinguish between Hsc70 and Hsp90; others, such as that in CHIP, can bind either Hsc70 or Hsp90 (11). The structural basis of Hsc70 and Hsp90 binding by TPR domains is known (25), and the residues required are absolutely conserved in FKBP38.

We hypothesize that as a membrane protein FKBP38 may provide a direct link between the cytosolic chaperones and ER retention or export mechanisms of HERG. Here we characterize the biochemical and functional effect of FKBP38 on WT HERG and a HERG trafficking mutant. Our results indicate that FKBP38 is important for the trafficking of WT HERG and is capable of rescuing the LQT2 HERG trafficking mutant F805C.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Preparation of cDNA Constructs—The generation of N-terminal Myc-tagged and N-terminal hemagglutinin (HA)-tagged HERG has been described previously (26). The HERG missense mutant F805C was engineered using the QuikChange XL site-directed mutagenesis kit (Stratagene) and a HERG-C cassette as the PCR template as described previously (26). The cDNA of HA-tagged FKBP38 was kindly provided by Dr. Nakayama (Fukuoka, Japan) (27).

Cell Culture and Transfection—HEK-293 and HL-1 cells were used and maintained as previously described (26). HEK-293 cells were cultured in {alpha}-minimal essential medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were cultured at 37 °C in 5% CO2. Transfections were carried out using either Lipofectamine or Lipofectamine 2000 as described by the manufacturer. HEK-293 cells were not used beyond 30 passages.

Stable Cell Line Generation—A stable cell line for WT HERG was generated using the G-418 selection method. Briefly, transfected cells were maintained in {alpha}-minimal essential medium supplemented with 800 µg/ml of G-418 (Invitrogen) for 10 to 15 days. G-418-resistant colonies were selected by their protein expression levels and purity as determined by Western blot analysis and immunocytochemistry.

Mass Spectrometry Analysis and Data Base Mining—Four proteomic screens of immunoprecipitated Myc-tagged HERG transfected into cardiac (HL-1) (28, 29) and non-cardiac (HEK-293) cell lines were performed. The Myc-immunoprecipitated HERG-bound complexes were separated by SDS-PAGE and stained by Coomassie blue. Individual bands were destained, excised, reduced, sulfur-alkylated, and digested with trypsin using a robotic digester (Micromass) at the Protein Unit Facility of the Genome Quebec Proteomics Platform. The resultant peptide mixtures were analyzed by direct on-line liquid chromatography tandem mass spectrometry (LC-MS/MS). The MS/MS spectra were evaluated using Mascot software (Matrix Science) to identify tryptic peptide sequences matched to the National Center for Biotechnology Information (NCBI) non-redundant protein and nucleotide data bases (dbEST) with a confidence level of 95% or greater (30). Peptide sequence tags were generated from the MS/MS spectra as described (31). The location and function of each identified protein were assigned using NCBI, Swiss-Prot, InterProHome, and InterProScan data bases.

Immunoprecipitation and Western Blotting—Twenty four hours post-transfection, cells were washed two times with cold PBS and then incubated in lysis buffer (0.5% Nonidet P-40, 75 mM NaCl, and 50 mM Tris, pH 8) plus a protease inhibitor mixture (Roche Applied Science) for a minimum of 15 min. Cells were homogenized by pipetting, harvested, and then left on ice for an additional 15 min with occasional vortexing. Detergent-insoluble material was sedimented at 16,000 x g for 30 min after which the resulting supernatant was collected and the protein concentration was determined with a detergent-compatible assay according to the manufacturer's instructions (Bio-Rad). For immunoprecipitation, samples of 0.5 to 1 mg of protein were incubated in a volume of 0.5 to 1 ml and incubated overnight at 4 °C with either monoclonal mouse {alpha}-Myc (Santa Cruz Biotechnology, Inc.) (1:100), monoclonal mouse {alpha}-HA (Covance) (1:100), or polyclonal rabbit {alpha}-FKBP38 (1:200) provided by Dr. Nakayama (Fukuoka, Japan). The immunoprecipitation samples were incubated with Protein A-Sepharose beads for 2 h after which the beads were washed extensively and then resuspended in sample buffer 2x (12% 0.5 M Tris, pH 6.8, 5% beta mercaptoethanol, 20% glycerol, 20% SDS, Bromphenol blue). Samples were resolved on a 7.5% polyacrylamide SDS gel and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked for 1 h with 5% nonfat dry milk and 0.1% Tween 20 in PBS and then incubated with the appropriate primary antibody for 1 h at room temperature, washed extensively, and then incubated with goat {alpha}-mouse/rabbit IgG conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories). After extensive washing the membranes were visualized on x-ray films using the ECL Plus detection kit (Amersham Biosciences).

Overexpression and siRNA—For all overexpression experiments, HEK-293 cells grown on 35-mm dishes were transiently transfected at 70-80% confluence with WT or F805C HERG and varying amounts of HA-FKBP38 (0, 0.2, or 0.4 µg) and an appropriate amount of empty vector to equalize total amount of transfected cDNA. After 48 h, cells were lysed as described above and equal amounts of protein were loaded and subjected to SDS-PAGE and Western blot analysis. For siRNA experiments, siRNA oligonucleotides targeting the 5'-AAGAGUGGCUGGACAUUCUGG-3' sequence in the open reading frame of human FKBP38 mRNA and a control double-stranded RNA with a corresponding scrambled sequence (5'-AAGCGCGCUUUGUAGGAUUC-3') were obtained from Dharmacon Research (Lafyette, CO) based on Ref. 27. HEK-293 cells stably expressing Myc-HERG-WT were seeded at low confluence (20-30%) on 35-mm dishes and transfected with siRNA oligonucleotides according to the manufacturer's instructions using Lipofectamine and Lipofectamine Plus Reagent (Invitrogen). Cells were lysed 2, 4, or 6 days post-transfection and subjected to SDS-PAGE and Western blot analysis as described above.

Immunolocalization—HEK-293 cells stably expressing WT HERG-Myc were seeded onto gelatin/fibronectin-coated coverslips. 24 h post-seeding, cells were washed with PBS and then fixed for 15 min with 4% formaldehyde at room temperature on an orbital shaker. Cells were then washed with PBS and permeabilized with 0.5% Triton X-100 in PBS for 5 min. Nonspecific antibody binding was blocked by PBS containing 10% goat serum for 30 min at room temperature after which cells were incubated with blocking solution containing either {alpha}-Myc (1:1000), {alpha}-KDEL (1:600), or {alpha}-FKBP38 (1:1000) antibody for 1 h. Coverslips were extensively washed before being incubated with blocking solution containing either Alexa Fluor 488-conjugated mouse secondary antibody or Alexa Fluor 633-conjugated rabbit secondary antibody at 1:400. After washing with PBS the coverslips were mounted onto glass slides using Immuno-Fluore Mounting Medium (ICN Biomedicals). Images were acquired with a Zeiss Axiovert 200 automated inverted microscope.

Densitometry and Statistical Analysis—Densitometric analysis was carried out using the digital imaging program ImageJ (National Institutes of Health). Each band was quantified by a mean pixel value after subtraction of background. Pixel values for the upper and lower HERG bands and the FKBP38 band were normalized to the loading control protein PP2A. For both the siRNA and overexpression experiments, HERG trafficking efficiency is represented by the ratio of the normalized HERG upper band to the total normalized HERG intensity (HERG upper + HERG lower). All experiments were repeated in triplicate. Paired t tests were used to compare groups of data to determine significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
HERG Interacts with Cytosolic Chaperones—To search for other possible chaperones or co-chaperones that interact with HERG we conducted a total of four proteomic screens of immunoprecipitated Myc-tagged HERG transfected into cardiac (HL-1) (28, 29) and non-cardiac (HEK-293) cell lines. The Myc-immunoprecipitated HERG-bound complexes were separated by SDS-PAGE, excised, subjected to tryptic digestion, and then analyzed by tandem mass spectrometry at the Montreal Genome Centre. Identified HERG-interacting chaperones and co-chaperones include Hsc70, Hsp90, Hdj2, Hop, Bag-2, and calnexin (Table 1). In addition to these abundant cytosolic chaperones we identified the immunophilin FKBP38, a putative co-chaperone that may interact with the Hsc70/Hsp90 chaperone network involved in the HERG processing pathway.


View this table:
[in this window]
[in a new window]

  		TABLE 1
Identified HERG-interacting chaperones and co-chaperones

Four proteomic screens of immunoprecipitated Myc-tagged HERG transfected into cardiac and non-cardiac cell lines were performed. The Myc-immunoprecipitated HERG-bound complexes were separated by SDS-PAGE. Individual bands were digested at the Protein Unit Facility of the Genome Quebec Proteomics Platform. The resultant peptide mixtures were analyzed by direct on-line liquid chromatography tandem mass spectrometry (LC-MS/MS). The MS/MS spectra were evaluated using Mascot software to identify tryptic peptide sequences matched to the NCBI non-redundant protein and nucleotide data bases (dbEST) with a confidence level of 95% or greater. The location and function of each identified protein were assigned using NCBI, Swiss-Prot, InterProHome and InterProScan data bases.

 
HERG and FKBP38 Co-immunoprecipitate and Co-localize—Although FKBP38 is ubiquitously expressed, it is found in greatest abundance in the brain and the heart (24). To confirm that there is an interaction between HERG and FKBP38 we conducted co-immunoprecipitation experiments. First, HEK-293 cells were transiently transfected with HA-tagged WT HERG and then lysed and immunoprecipitated with an antibody against endogenous FKBP38. As shown in Fig. 1A, both the mature and immature forms of HERG were immunoprecipitated with the {alpha}-FKBP38 antibody. It remains unclear whether FKBP38 truly interacts with both forms of the HERG protein, given that most chaperones release their substrate once it has reached its native state. It seems conceivable that FKBP38 is bound to HERG even after its release from the ER. This might be expected if FKBP38 is involved in a late HERG folding stage or in the ER exit of HERG. Second, we transiently transfected HEK-293 cells with HA vector alone, HA-tagged WT HERG, Myc vector alone, or Myc-tagged WT HERG and then lysed and immunoprecipitated with either {alpha}-HA or {alpha}-Myc antibody. Fig. 1B shows the presence of a band at ~62 kDa that corresponds to FKBP38, indicating that endogenous FKBP38 is immunoprecipitated with both Myc-tagged and HA-tagged WT HERG but not with the vectors alone. Finally, immunoprecipitation studies were conducted in HEK-293 cells alone or stably expressing Myc-tagged WT HERG and in AP-1 cells stably expressing the HA-tagged sodium-hydrogen exchanger NheI. Fig. 1C shows that stably expressed Myc-tagged HERG can precipitate endogenous FKBP38 whereas the stably expressed HA-tagged sodium-hydrogen exchanger NheI cannot. Taken together these results indicate that HERG and FKBP38 do indeed interact and predict that the two proteins are present in the same cellular compartments.

FKBP38 primarily localizes to the outer membrane of the mitochondria through its C-terminal membrane anchor where it is proposed to play a role in the regulation of apoptosis through its interaction with Bcl-2 (27). Recent immunofluorescence and cell fractionation data indicate that FKBP38 resides at both the ER and mitochondrial membranes (27, 32, 33). To first confirm the ER localization of FKBP38 in our system we performed immunolocalization experiments in HEK-293 and HL-1 cells. As shown in Fig. 2 there is overlap between the ER marker ({alpha}-KDEL antibody) and FKBP38 indicating that FKBP38 is localized to the ER as well as the mitochondria. To determine whether HERG and FKBP38 co-localize in our cell system we co-stained HEK-293 cells stably expressing Myc-tagged HERG with an {alpha}-Myc antibody (mouse) and an {alpha}-FKBP38 antibody (rabbit). Fig. 3A displays the clear overlap between the two proteins indicating that they co-localize in HEK-293 cells. To determine whether these two proteins also co-localize in a more physiological system, we transfected HA-tagged HERG into a cardiac cell line (HL-1) and co-stained with an {alpha}-HA antibody for HERG and an {alpha}-FKBP38 antibody for endogenous FKBP38. Fig. 3B shows that similar to what was found in the HEK-293 cells, when the HL-1 cells were transfected with HERG there is co-localization of HERG and FKBP38 that appears as a perinuclear staining pattern (Fig. 3B). Taken together, these results show that FKBP38 is expressed in the ER where it co-localizes with HERG.


Figure 1
View larger version (44K):
[in this window]
[in a new window]

  		FIGURE 1.
Immunoprecipitation of HERG and FKBP38. A, lysates of HEK-293 cells alone (C) or HEK-293 cells transiently transfected with HA-HERG (HG-HA) were immunoprecipitated with {alpha}-FKBP38 antibody. Membranes were blotted with {alpha}-HA for HERG visualization. B, HEK-293 cells were transiently transfected with either HA vector, HA-tagged WT HERG, Myc vector, or Myc-tagged WT HERG, lysed, and immunoprecipitated with {alpha}-Myc or {alpha}-HA antibody as indicated. Membranes were blotted for endogenous FKBP38 visualization with an {alpha}-FKBP38 antibody. C, lysates of HEK-293 cells alone (HEK) or HEK-293 cells stably expressing Myc-HERG-WT (Myc-HG) were lysed and immunoprecipitated with {alpha}-Myc antibody. As a negative control AP-1 cells stably expressing HA-NheI were lysed and immunoprecipitated with {alpha}-HA. Membranes were blotted with {alpha}-FKBP38 for endogenous FKBP38 visualization.

 


Figure 2
View larger version (69K):
[in this window]
[in a new window]

  		FIGURE 2.
FKBP38 co-localizes with an ER marker in HEK-293 cells. Immunolocalization experiments were performed using a monoclonal {alpha}-KDEL and polyclonal {alpha}-FKBP38 primary antibody followed by Alexa488 (green)/Alexa633 (red)-conjugated secondary antibodies, respectively.

 


Figure 3
View larger version (100K):
[in this window]
[in a new window]

  		FIGURE 3.
HERG co-localizes with FKBP38 in a cardiac (HL-1) and a non-cardiac (HEK-293) cell line. A, immunolocalization experiments were performed in HEK-293 cells stably expressing Myc-tagged HERG. HERG and FKBP38 were visualized using a monoclonal {alpha}-Myc and polyclonal {alpha}-FKBP38 primary antibody followed by Alexa488 (green)/Alexa633 (red)-conjugated secondary antibodies, respectively. B, HL-1 cells transfected with HA-tagged HERG were visualized as described for panel A, except that {alpha}-HA was used instead of {alpha}-Myc for HERG visualization. For panels A and B the third panel represents a merged image to demonstrate the overlap of the proteins.

 
FKBP38 Knock Down Reduces HERG Trafficking—To determine whether the interaction between HERG and FKBP38 has a role in the trafficking of HERG we used siRNA to reduce the level of FKBP38 expression in the HEK-293 cell model. Under control conditions, both the immature, core glycosylated ER form and the mature complex glycosylated form of HERG were observed by Western blot at days 2, 4, and 6 post-transfection. The targeted siRNA reduction of FKBP38 caused a marked diminution of FKBP38 expression by 2 days post-transfection whereas a double-stranded scrambled oligonucleotide had no effect on the expression level of FKBP38 (Fig. 4A). Importantly, this FKBP38 knock down on day 2 led to a statistically significant reduction in the HERG trafficking efficiency relative to control (HG upper/HG total) on day 4 (15.0 ± 1.8 relative to control 36.8 ± 8.4 arbitrary units (AU); p = 0.03) and day 6 (24.6 ± 1.24 relative to control 41.5 ± 5.5 AU; p = 0.02; Fig. 4B). We attribute the delay in the siRNA-induced FKBP38 reduction of HERG trafficking efficiency to the relative stabilities of FKBP38 and HERG. HERG is a stable protein with a half-life of ~12-16 h at the cell surface; thus, a maximal diminution of mature HERG would not be expected on day 2 when FKBP38 levels are minimal but rather at the next time point, on day 4 as observed. Thus, the reduction of FKBP38 expression results in a decrease in the efficiency of HERG maturation.


Figure 4
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 4.
FKBP38 knock down negatively influences HERG trafficking. A, human FKBP38 siRNA and a control double-stranded RNA interference were transfected into HEK-293 cells stably expressing Myc-HERG-WT using Lipofectamine Plus reagent. The reduction of the cellular FKBP38 and the expression of HERG were analyzed by Western blotting 2, 4, and 6 days after transfection. B, corresponding mean data (n = 3 experiments/condition). *, p = 0.03; #, p = 0.02 versus scrambled day 4 and scrambled day 6, respectively.

 


Figure 5
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 5.
Overexpression of FKBP38 partially rescues the trafficking of LQT2 trafficking-deficient mutants. A, HEK-293 cells were transiently transfected with HA-tagged WT HERG or F805C and indicated amounts of FKBP38 or empty vector. Two days post-transfection, cells were lysed and the expression of HERG was analyzed by Western blotting. B, corresponding mean data (n = 3 experiments/condition). *, p <0.01 versus F805C 0.0.

 
FKBP38 Rescues Trafficking of F805C—Given that siRNA knock down of FKBP38 reduced HERG maturation, we questioned whether overexpression of FKBP38 would augment HERG maturation and/or rescue a HERG trafficking mutant. To test these possibilities, we overexpressed HA-tagged FKBP38 in the presence of either WT HERG or the HERG trafficking mutant F805C. The F805C mutation is present in the cyclic nucleotide binding domain (34) and can be rescued by a reduction in temperature (35) or by the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin (34). As shown in Fig. 5A, FKBP38 (0.2 or 0.4 µg of cDNA) or empty vector were transfected along with WT HERG or F805C into HEK-293 cells and the resulting HERG expression was analyzed by Western blot. For WT HERG, neither level of FKBP38 overexpression had an effect on its trafficking efficiency (trafficking efficiency of 33.2 ± 10.7, 35.8 ± 6.7, and 33.7 ± 8.2 AU for WT with 0, 0.2, or 0.4 µg of FKBP38, respectively; Fig. 5B). However, as shown in Fig. 5A and quantified in Fig. 5B, overexpression of FKBP38 at both 0.2 and 0.4 µg of cDNA was able to partially rescue the trafficking of the F805C mutant (trafficking efficiency of 6.9 ± 2.5, 16.0 ± 2.5, and 19.5 ± 5.2 AU for F805C with 0, 0.2, or 0.4 µg of FKBP38, respectively), which is normally retained in the ER and seen on Western blot as a single band, even when twice as much total protein was loaded (data not shown). When the trafficking efficiency is compared between WT and F805C at 0.4 µg of FKBP38 cDNA (WT 33.7 ± 8.2 versus F805C 19.5 ± 5.2 AU) we see that the rescue is 58% of what is seen for WT HERG. This result indicates that a fraction of these channels have escaped the ER.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The major conclusion of this work is that FKBP38 interacts with the HERG potassium channel and influences its trafficking efficiency. This influence on trafficking is evident in two ways. Most importantly, overexpression of FKBP38 partially rescues the LQT2 trafficking mutant F805C. In addition, when FKBP38 protein expression levels are reduced by targeted siRNA, there is a corresponding reduction in WT HERG trafficking efficiency. We suggest that HERG and FKBP38 interact in the ER membrane late during HERG biogenesis and that this interaction is necessary for successful exit of HERG from the ER.


Figure 6
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 6.
Cytosolic chaperone networks. Hsc70 and Hsp90 are key cytosolic chaperones, and co-chaperones regulate their function. Hdj2 activates Hsc70. Hop, CHIP, FKBP52, and FKBP38 are TPR domain co-chaperones. Hop organizes Hsc70 and Hsp90; CHIP directs proteins to degradation but can be counteracted by Bag-2; FKBP52 and p23 complete the folding of steroid receptors. FKBP38 resides at the ER facing the cytosol, calnexin faces the lumen. We propose that FKBP38 acts with cytosolic chaperones to assist the quality control, folding, and export of HERG.

 
We propose a model in which FKBP38 acts to present HERG to the ER export machinery. The hypothesis that FKBP38 is involved in the late stage of the folding pathway of HERG and may be involved in ER export is supported by the observation that the majority of FKBP38 interacts with the immature ER form of HERG and there is a relatively minor interaction with the fully glycosylated form of HERG. The fact that a small amount of fully glycosylated HERG interacts with FKBP38 suggests that the two proteins are still bound as HERG is exported to the Golgi where complex glycosylation occurs. If FKBP38 facilitates the process by which HERG reaches its final native conformation, then it seems plausible that it may not immediately dissociate from HERG. To support this contention Fig. 3 demonstrates that the overlap between FKBP38 and HERG may not be solely restricted to the ER.

To date, most published accounts of FKBP38 describe its role in the regulation of apoptosis through its interaction with Bcl-2 (27, 32, 33, 36, 37). However, it has been proposed that some immunophilins can act as chaperones by binding unfolded polypeptides (38). As stated above, we are proposing a role for FKBP38 as a co-chaperone of the Hsc70/Hsp90 chaperone system of HERG. A similar suggestion has recently been put forward by Wang et al. (12) in the folding pathway of CFTR-{Delta}F508. This group used proteomics to identify what they refer to as the "CFTR interactome." This group of proteins consists of several co-chaperones of the Hsc70/Hsp90 chaperone network that differ in their interactions with {Delta}F508 and WT CFTR, including the co-chaperone FKBP38. Interestingly, there are differences between their results regarding the effect of FKBP38 on the trafficking of CFTR-{Delta}F508 and our results on the trafficking of HERG-F805C. Wang et al. (12) found that siRNA knock down of FKBP38 resulted in a reduction in both the ER and Golgi bands of CFTR-{Delta}F508. This is similar to the effect that siRNA knock down had on WT HERG trafficking. Interestingly, they found that overexpression of FKBP38 also caused a reduction in both ER and Golgi bands of CFTR-{Delta}F508. These results led them to postulate that FKBP38 function and expression are tied to the steady-state concentration of Hsp90 and assure optimal performance of the CFTR-specific Hsp90-client folding pathway. They concluded that FKBP38 influences the stability of CFTR-{Delta}F508 in the ER whereas we show that it affects HERG trafficking efficiency. To reconcile the differences in the effect of FKBP38 overexpression on CFTR {Delta}F508 versus HERG F805C, we suggest that the levels of co-chaperones needed for successful folding and export are protein- and possibly cell type-dependent. It would then follow that the same co-chaperones could have varying effects on different client proteins (i.e. HERG and CFTR).

The proposed co-chaperone role for FKBP38 is motivated in part by consideration of a similar immunophilin, FKBP52, which plays a role in steroid receptor activation (39). In the case of the steroid receptors, Hsc70 and Hsp90 work together with several nonessential, TPR domain-containing co-chaperones including FKBP52 to open a hydrophobic cleft in the native state of the steroid receptor (40). As shown in the left panel of Fig. 6, steroid receptors are bound early in biogenesis by both Hsc70 and Hdj-2, at which point Hjd-2 activates Hsc70. The activated receptor complex changes conformation such that it can bind Hsp90 and Hop. As the steroid binding cleft is opened, Hsp90 achieves its ATP-dependent conformation, Hop dissociates from the receptor-bound Hsp90, and p23 binds to Hsp90 (14). The dissociation of Hop from the receptor complex frees a TPR domain acceptor site on Hsp90 to bind the TPR domain of the immunophilin FKBP52. It is proposed that FKBP52 is responsible for the trafficking of steroid receptors to the nucleus upon steroid binding by acting to link them to cytoplasmic dynein for transport along the cytoskeleton into the nucleus (41-44). Given that many of the same chaperones and co-chaperones described above for FKBP52 were immunoprecipitated with HERG, we suggest that FKBP38 acts as an analogous Hsp90 co-chaperone in the WT HERG maturation pathway (Fig. 6, right panel). Specifically, we hypothesize that WT HERG is released from its final chaperone complex in a native folded state and exits the ER, possibly still in a complex with FKBP38. All interactions occur transiently and at no point are any of the chaperones or co-chaperones limiting to the process. FKBP38 could play a role in the attachment of HERG to the motor protein kinesin, as FKBP52 does with the steroid receptors and dynein, for transport to the plasma membrane via an interaction with the TPR domain of FKBP38 and the TPR domain at the C terminus of the kinesin light chain (45-47). Investigations are currently underway to test this hypothesis.

In contrast to WT HERG, F805C progresses through a similar processing pathway except that its interaction with the initial chaperone complex of Hdj-2, Hsc70, Hop, and Hsp90 is likely prolonged (8, 9). The F805C mutant is recognized by these chaperones as non-native, and additional attempts are likely made to properly fold the protein. If these attempts to fold the protein fail, then it is expected that CHIP would replace Hop on Hsc70, which then targets the mutant protein for degradation as is known to occur with the trafficking-defective CFTR mutant {Delta}F508 (20, 21). Recent work has demonstrated for the first time that FKBP38 interacts with Hsp90 through its TPR domain and that FKBP38 is inhibited by Hsp90 (37). One speculation is that FKBP38 and Hsp90 function in opposition with respect to the trafficking of HERG mutants and that the interaction of FKBP38 with HERG and Hsp90 somehow facilitates the release of the channel.

The fact that FKBP38 overexpression rescued the trafficking of F805C suggests that it may be a limiting co-chaperone in this pathway. Of interest is the fact that although FKBP38 overexpression rescued the trafficking of F805C, it had no effect on the trafficking efficiency of WT HERG. Precedence exists in the literature demonstrating that rescue of a trafficking mutant does not always correlate with an increased efficiency of WT trafficking. Ficker et al. (35) showed that E4031, cisapride, and quinidine all rescued the trafficking of the HERG trafficking mutant G601S, but none of the compounds had an effect on the trafficking efficiency of WT HERG.

Given the fact that no compound currently exists that is capable of rescuing all HERG trafficking mutants, it is likely that HERG has multiple ER exit strategies. The current research provides one example of a HERG trafficking mutant that can be rescued by overexpression of FKBP38. It is entirely possible that a different balance of co-chaperones is required to rescue different HERG trafficking mutants.


   FOOTNOTES
 
* This work was supported by grants from the Canadian Institute of Health Research (to A. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Dept. of Physiology, McGill University, 3655 Rue Sir William Osler, Montreal, Quebec H3G 1Y6, Canada. Tel.: 514-398-2272; Fax: 514-398-7452; E-mail: alvin.shrier{at}mcgill.ca.

2 The abbreviations used are: LQTS, long QT syndrome; HERG, human ether-a-go-go-related gene; WT, wild type; ER, endoplasmic reticulum; Hsc70, 70-kDa heat shock cognate protein; Hsp90, 90-kDa heat shock protein; CFTR, cystic fibrosis transmembrane conductance regulator; CHIP, C-terminal of Hsp70-interacting protein; Bag-2, BCL-associated athanogene 2; Hop, Hsp-organizing protein; FKBP38, 38-kDa FK506-binding protein; TPR, tetratricopeptide repeat; HA, hemagglutinin; HERG-C, C terminus of HERG; HEK, human embryonic kidney; PBS, phosphate-buffered solution; siRNA, small interfering RNA; AU, arbitrary units. Back


   ACKNOWLEDGMENTS
 
We thank K. I. Nakayama for the FKBP38 clone and the rabbit antiserum to FKBP38, Y. Q. Zhao for excellent technical support, and J. C. Young for many stimulating discussions and creation of Fig. 6.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995) Cell 80, 795-803[CrossRef][Medline] [Order article via Infotrieve]
  2. Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995) Cell 81, 299-307[CrossRef][Medline] [Order article via Infotrieve]
  3. Anderson, C. L., Delisle, B. P., Anson, B. D., Kilby, J. A., Will, M. L., Tester, D. J., Gong, Q., Zhou, Z., Ackerman, M. J., and January, C. T. (2006) Circulation 113, 365-373[Abstract/Free Full Text]
  4. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T. (1998) Biophys. J. 74, 230-241[Medline] [Order article via Infotrieve]
  5. Petrecca, K., Atanasiu, R., Akhavan, A., and Shrier, A. (1999) J. Physiol. 515, Pt. 1, 41-48[Abstract/Free Full Text]
  6. Gong, Q., Anderson, C. L., January, C. T., and Zhou, Z. (2002) Am. J. Physiol. 283, H77-H84
  7. Ellgaard, L., and Helenius, A. (2003) Nat. Rev. Mol. Cell. Biol. 4, 181-191[CrossRef][Medline] [Order article via Infotrieve]
  8. Ficker, E., Dennis, A. T., Wang, L., and Brown, A. M. (2003) Circ. Res. 92, e87-e100[Abstract/Free Full Text]
  9. Gong, Q., Jones, M. A., and Zhou, Z. (2006) J. Biol. Chem. 281, 4069-4074[Abstract/Free Full Text]
  10. McClellan, A. J., Tam, S., Kaganovich, D., and Frydman, J. (2005) Nat. Cell Biol. 7, 736-741[CrossRef][Medline] [Order article via Infotrieve]
  11. Young, J. C., Agashe, V. R., Siegers, K., and Hartl, F. U. (2004) Nat. Rev. Mol. Cell Biol. 5, 781-791[CrossRef][Medline] [Order article via Infotrieve]
  12. Wang, X., Venable, J., LaPointe, P., Hutt, D. M., Koulov, A. V., Coppinger, J., Gurkan, C., Kellner, W., Matteson, J., Plutner, H., Riordan, J. R., Kelly, J. W., Yates, J. R., III, and Balch, W. E. (2006) Cell 127, 803-815[CrossRef][Medline] [Order article via Infotrieve]
  13. Riordan, J. R. (2005) Annu. Rev. Physiol. 67, 701-718[CrossRef][Medline] [Order article via Infotrieve]
  14. Hernandez, M. P., Sullivan, W. P., and Toft, D. O. (2002) J. Biol. Chem. 277, 38294-38304[Abstract/Free Full Text]
  15. Yang, Y., Janich, S., Cohn, J. A., and Wilson, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9480-9484[Abstract/Free Full Text]
  16. Pind, S., Riordan, J. R., and Williams, D. B. (1994) J. Biol. Chem. 269, 12784-12788[Abstract/Free Full Text]
  17. Loo, M. A., Jensen, T. J., Cui, L., Hou, Y.-X., Chang, X.-B., and Riordan, J. R. (1998) EMBO J. 17, 6879-6887[CrossRef][Medline] [Order article via Infotrieve]
  18. Meacham, G. C., Lu, Z., King, S., Sorscher, E., Tousson, A., and Cyr, D. M. (1999) EMBO J. 18, 1492-1505[CrossRef][Medline] [Order article via Infotrieve]
  19. Youker, R. T., Walsh, P., Beilharz, T., Lithgow, T., and Brodsky, J. L. (2004) Mol. Biol. Cell 15, 4787-4797[Abstract/Free Full Text]
  20. Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M., and Cyr, D. M. (2001) Nat. Cell Biol. 3, 100-105[CrossRef][Medline] [Order article via Infotrieve]
  21. Younger, J. M., Ren, H.-Y., Chen, L., Fan, C.-Y., Fields, A., Patterson, C., and Cyr, D. M. (2004) J. Cell Biol. 167, 1075-1085[Abstract/Free Full Text]
  22. Arndt, V., Daniel, C., Nastainczyk, W., Alberti, S., and Hohfeld, J. (2005) Mol. Biol. Cell 16, 5891-5900[Abstract/Free Full Text]
  23. Peattie, D. A., Harding, M. W., Fleming, M. A., DeCenzo, M. T., Lippke, J. A., Livingston, D. J., and Benasutti, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10974-10978[Abstract/Free Full Text]
  24. Lam, E., Martin, M., and Wiederrecht, G. (1995) Gene 160, 297-302[CrossRef][Medline] [Order article via Infotrieve]
  25. Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., and Moarefi, I. (2000) Cell 101, 199-210[CrossRef][Medline] [Order article via Infotrieve]
  26. Akhavan, A., Atanasiu, R., and Shrier, A. (2003) J. Biol. Chem. 278, 40105-40112[Abstract/Free Full Text]
  27. Shirane, M., and Nakayama, K. I. (2003) Nat. Cell Biol. 5, 28-37[CrossRef][Medline] [Order article via Infotrieve]
  28. Claycomb, W. C., Lanson, N. A., Jr., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., and Izzo, N. J., Jr. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2979-2984[Abstract/Free Full Text]
  29. White, S. M., Constantin, P. E., and Claycomb, W. C. (2004) Am. J. Physiol. 286, H823-H829
  30. Perkins, D. N., Pappin, D. J. C., Creasy, D. M., and Cottrell, J. S. (1999) Electrophoresis 20, 3551-3567[CrossRef][Medline] [Order article via Infotrieve]
  31. Mann, M., and Wilm, M. (1994) Anal. Chem. 66, 4390-4399[Medline] [Order article via Infotrieve]
  32. Edlich, F., Weiwad, M., Erdmann, F., Fanghanel, J., Jarczowski, F., Rahfeld, J.-U., and Fischer, G. (2005) EMBO J. 24, 2688-2699[CrossRef][Medline] [Order article via Infotrieve]
  33. Kang, C. B., Tai, J., Chia, J., and Yoon, H. S. (2005) FEBS Lett. 579, 1469-1476[CrossRef][Medline] [Order article via Infotrieve]
  34. Delisle, B. P., Anderson, C. L., Balijepalli, R. C., Anson, B. D., Kamp, T. J., and January, C. T. (2003) J. Biol. Chem. 278, 35749-35754[Abstract/Free Full Text]
  35. Ficker, E., Obejero-Paz, C. A., Zhao, S., and Brown, A. M. (2002) J. Biol. Chem. 277, 4989-4998[Abstract/Free Full Text]
  36. Kang, C. B., Feng, L., Chia, J., and Yoon, H. S. (2005) Biochem. Biophys. Res. Commun. 337, 30-38[CrossRef][Medline] [Order article via Infotrieve]
  37. Edlich, F., Erdmann, F., Jarczowski, F., Moutty, M.-C., Weiwad, M., and Fischer, G. (2007) J. Biol. Chem. 282, 15341-15348[Abstract/Free Full Text]
  38. Schiene-Fischer, C., and Yu, C. (2001) FEBS Lett. 495, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  39. Pratt, W. B., and Toft, D. O. (2003) Exp. Biol. Med. 228, 111-133[Abstract/Free Full Text]
  40. Pratt, W. B., Galigniana, M. D., Morishihiro, Y., and Murphy, P. J. M. (2004) Essays Biochem. 40, 41-58[Medline] [Order article via Infotrieve]
  41. Pratt, W. B., Silverstein, A. M., and Galigniana, M. D. (1999) Cell. Signal. 11, 839-851[CrossRef][Medline] [Order article via Infotrieve]
  42. Silverstein, A. M., Galigniana, M. D., Kanelakis, K. C., Radanyi, C., Renoir, J.-M., and Pratt, W. B. (1999) J. Biol. Chem. 274, 36980-36986[Abstract/Free Full Text]
  43. Galigniana, M. D., Radanyi, C., Renoir, J.-M., Housley, P. R., and Pratt, W. B. (2001) J. Biol. Chem. 276, 14884-14889[Abstract/Free Full Text]
  44. Galigniana, M. D., Harrell, J. M., Murphy, P. J., Chinkers, M., Radanyi, C., Renoir, J. M., Zhang, M., and Pratt, W. B. (2002) Biochemistry 41, 13602-13610[CrossRef][Medline] [Order article via Infotrieve]
  45. Sarah, A., Jolante, R., Friederike, B., and Günther, W. (2006) J. Muscle Res. Cell Motil. 27, 153-160[CrossRef][Medline] [Order article via Infotrieve]
  46. Wozniak, M. J., and Allan, V. J. (2006) EMBO J. 25, 5457-5468[CrossRef][Medline] [Order article via Infotrieve]
  47. Hirokawa, N. (1998) Science 279, 519-526[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
V. L. Patterson, C. Damrau, A. Paudyal, B. Reeve, D. T. Grimes, M. E. Stewart, D. J. Williams, P. Siggers, A. Greenfield, and J. N. Murdoch
Mouse hitchhiker mutants have spina bifida, dorso-ventral patterning defects and polydactyly: identification of Tulp3 as a novel negative regulator of the Sonic hedgehog pathway
Hum. Mol. Genet., May 15, 2009; 18(10): 1719 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
D. P. McEwen and J. R. Martens
Antifibrillatory Agents and Potassium Channels in the Atria: Pore Block versus Channel Trafficking
Mol. Interv., April 1, 2009; 9(2): 79 - 86.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Wang, B. D. Fonseca, H. Tang, R. Liu, A. Elia, M. J. Clemens, U.-A. Bommer, and C. G. Proud
Re-evaluating the Roles of Proposed Modulators of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling
J. Biol. Chem., November 7, 2008; 283(45): 30482 - 30492.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
M. Shirane, M. Ogawa, J. Motoyama, and K. I. Nakayama
Regulation of apoptosis and neurite extension by FKBP38 is required for neural tube formation in the mouse.
Genes Cells, June 1, 2008; 13(6): 635 - 651.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/32/23509    most recent
M701006200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, V. E.
Right arrow Articles by Shrier, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, V. E.
Right arrow Articles by Shrier, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement